DC
PTCT icon

Davenport & Co’s PTC Therapeutics PTCT Stock Holding History

Davenport & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-82,200
Closed -$1.15M – 655
2016
Q3 		$1.15M Hold
82,200
– – 0.02% 273
2016
Q2 		$577K Buy
82,200
+2,600
+3% +$19.1K 0.01% 374
2016
Q1 		$513K Buy
79,600
+1,100
+1% +$19.1K 0.01% 372
2015
Q4 		$2.54M Sell
78,500
-17,700
-18% -$521K 0.04% 181
2015
Q3 		$2.57M Buy
96,200
+30,747
+47% +$1.32M 0.04% 180
2015
Q2 		$3.15M Buy
65,453
+500
+0.8% +$29.2K 0.05% 179
2015
Q1 		$3.95M Buy
64,953
+18,853
+41% +$1.15M 0.06% 169
2014
Q4 		$2.39M Hold
46,100
– – 0.04% 199
2014
Q3 		$2.03M Buy
46,100
+31,100
+207% +$973K 0.04% 209
2014
Q2 		$392K Buy
+15,000
New +$321K 0.01% 412

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Davenport & Co's PTCT Position: Q4 2016 in Review

Davenport & Co sold out of PTC Therapeutics (PTCT) in Q4 2016, closing a stake of 82,200 shares — an estimated $1.15M sold.

Davenport & Co first reported a position in PTCT in Q2 2014 and held it in 10 quarters. The position peaked at $3.95M in Q1 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

  • Davenport & Co reported no remaining PTC Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Davenport & Co sold 82,200 PTC Therapeutics shares in Q4 2016, an estimated $1.15M.
  • Davenport & Co first reported a position in PTC Therapeutics in Q2 2014 and held it in 10 quarters.
  • Davenport & Co's PTC Therapeutics position peaked at $3.95M in Q1 2015.
  • 123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on Davenport & Co's 13F filing for Q4 2016, filed 5 Jan 2017.